三爱健康集团(01889) - 2025 - 年度业绩

Fund Allocation - The company plans to allocate approximately 45% of the net proceeds from the issuance of convertible bonds for the purchase of production facilities, equipment, and raw materials for pharmaceutical products [2]. - About 30% of the net proceeds will be used to enrich the pharmaceutical product base, including the development of new drugs and/or obtaining drug licenses [2]. - Approximately 25% of the net proceeds will be allocated to increase sales points and additional sales personnel costs [2].